Compare Sanofi SA (SNY) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.05 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| SNY | VIG | |
|---|---|---|
Market Cap | $95.18B | $132.40B |
Volume | 2,995,646 | 1,287,188 |
Sector | Health | — |
52-Week High | $52.34 | $246.61 |
52-Week Low | $39.51 | $210.70 |
Typical Hold Time | 94 Days | 134 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
VIG trades at $237.39, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on dividend growth stocks with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5% year-to-date, though growth remains below historical averages. Technical indicators show support at $235-236 and resistance at $238-240.
Outlook remains positive for long-term investors seeking dividend growth, though the strategy sacrifices current yield for quality. Risks include slower dividend growth rates and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may underperform during high-yield market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
